Sign in Subscribe
Class action lawsuits

Class Action Lawsuit Filed Against Hims & Hers Health Over Alleged Securities Fraud

Strategic Insights

— 1 min read

Pomerantz LLP has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) alleging that the company and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. The lawsuit concerns the company's deceptive promotion and sale of illegitimate, knockoff versions of Wegovy, a medication approved by the FDA, which has put patient safety at risk. The partnership between Hims & Hers and Novo Nordisk was terminated due to these actions, causing Hims & Hers' stock price to fall by 34.63% on June 23, 2025.

Key Takeaways:

  • The class action lawsuit alleges that Hims & Hers and its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • The company is accused of promoting and selling illegitimate, knockoff versions of Wegovy, a medication approved by the FDA, which has put patient safety at risk.
  • The partnership between Hims & Hers and Novo Nordisk was terminated due to the company's actions.
  • Hims & Hers' stock price fell by 34.63% on June 23, 2025, following the announcement of the partnership termination.
  • The lawsuit is seeking damages on behalf of investors who purchased or otherwise acquired Hims & Hers securities during the Class Period.
  • The complaint can be obtained at no charge at
  • Pomerantz LLP is one of the premier firms in the areas of corporate, securities, and antitrust class litigation.

Statistics:

  • Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.
  • The lawsuit is seeking damages on behalf of investors who purchased or otherwise acquired Hims & Hers securities during the Class Period, which includes up to August 25, 2025.
  • Pomerantz LLP has recovered numerous multimillion-dollar damages awards on behalf of class members.

Sources:

  • Pomerantz LLP, (no date)
  • "Novo Nordisk Terminates Partnership with Hims & Hers Over Alleged Deceptive Practices," Novo Nordisk, June 23, 2025
  • Pomerantz LLP, (no date)

Read more